France: ‘Humiliation’ & the Sanofi-Pfizer Vaccine Deal;…
The latest from French pharma where Sanofi has inked a deal to produce 125 million doses of Pfizer’s COVID-19 vaccine as it faces delays with its…
Tagged with Ipsen
Ipsen CEO David Loew on M&A, Rare Disease Expansion, Niche…
In a wide-ranging and exclusive interview with PharmaBoardroom, Ipsen CEO David Loew looks back on an atypical first 100 days at the helm of the…
Ipsen CEO David Loew: Pharma Has to Play “A Wider Role” in…
Ipsen CEO David Loew took aim at the lip service often paid to the notion of ‘patient-centricity’ in pharma in conversation at the FT’s Global…
France: Mid-2021 for Sanofi COVID-19 Vaccine; 1 Million Domestic…
A roundup of the latest stories from French pharma, including the progress of Sanofi’s COVID-19 vaccine, how Ipsen has managed to achieve sales…
French Pharma News Roundup August 2020
A roundup of some of the latest from French pharma, including Sanofi’s bumper Prinicipia deal, how Unither’s new Chinese acquisition catapults it…
New CEO for Ipsen as David Loew Makes Switch From Sanofi Pasteur
David Loew, formerly executive vice president of Sanofi Pasteur, Sanofi's vaccines division, was appointed CEO of fellow French firm Ipsen on the 28th…
The UAE: A Gathering Force
Accounting for less than two percent of the global pharmaceutical market, the Middle East has long been somewhat overlooked by many drug makers, most…
Mauricio Guizar – General Manager, Ipsen Mexico
Mauricio Guizar, newly appointed general manager of Ipsen Mexico since October 2019, shares his first impression of the French specialty care…
Amalia Mihai – Market Access Manager, Ipsen Romania
Amalia Mihai, market access manager of Ipsen Romania explains that over the course of 26 years Ipsen has been increasingly helping Romanian patients…
A New Era of Access to Innovation in the Czech Republic?
Pharma industry stakeholders are generally quick to suggest that the Czech Republic is one of the most over-regulated markets in Europe, with new or…
Patrik Zachar – Vice President Central Europe, Ipsen
Patrik Zachar, Vice President Central Europe of Ipsen, shares how the company has built a strong presence in oncology and neuroscience in the CE…
Problems Pile Up at Ipsen after Further Clinical Setback
These are worrying times for iconic French mid-cap Ipsen. Trials for palovarotene, a treatment for rare bone disorders, have been plagued by setbacks,…
